2.1. Study Population
bleeding, seizure, cancer, vaginal atrophy, diabetes
BLEEDING, CANCER, LIVER DISEASE, VAGINAL ATROPHY, AUTOIMMUNE DISEASE, DIABETES
In the present randomized clinical trial, postmenopausal women with vaginal atrophy who complained of menopausal symptoms were recruited at Shahid Beheshti Hospital, Kashan, Iran, from February to December 2021. The study was approved by the Ethics Committee of the Kashan University of Medical Sciences (IR.KAUMS.MEDNT.REC.1399.206), and the trial was registered at IRCT20210405050859N1. All participants were informed of the protocol and purpose of the study. Informed consent was obtained from participants before they took part in the study.A total of 63 postmenopausal women were enrolled in this study. The inclusion criteria were as follows: women aged >40 years old who had natural menopause and last menstrual bleeding at least 12 months before. The exclusion criteria were as follows: sensitivity to hormonal therapy, cancer, autoimmune disease, smoking or alcohol consumption, liver disease, diabetes, and seizure.